A benzamide HBV capsid protein inhibitor and its preparation method and application

By developing benzamide HBV capsid protein inhibitors, the side effects, drug resistance and low cure rates of existing HBV therapeutic drugs have been solved, significant anti-HBV activity has been demonstrated, and new anti-hepatitis B drug development direction has been provided. .

CN116410106BActive Publication Date: 2024-12-06WEIFANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310392180.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-13
Publication Date
2024-12-06
Estimated Expiration
2043-04-13

AI Technical Summary

Technical Problem

Existing hepatitis B virus (HBV) therapeutic drugs such as PEG-IFNα and nucleoside analogs have side effects, drug resistance and low cure rates, and cannot completely eliminate hepatitis B virus in the body. It requires long-term medication, and HBV capsid protein inhibitors There is no breakthrough in research.

Method used

A benzamide HBV capsid protein inhibitor was developed, prepared by a specific synthetic route, demonstrating anti-HBV activity as a non-nucleoside HBV inhibitor for the preparation of anti-hepatitis B drugs.

Benefits of technology

It demonstrated significant anti-HBV activity, with an EC50 value lower than the lead compound NVR 3-778, which has potential advantages in the treatment of HBV and provides a new direction for the development of anti-hepatitis B drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116410106B_ABST
    Figure CN116410106B_ABST
Patent Text Reader

Abstract

The present invention discloses a benzamide HBV capsid protein inhibitor and its preparation method and application. The compound has a structure shown in general formula I or II. The present invention also relates to a preparation method of a compound containing the structure of general formula I or II, a pharmaceutical composition, and the application of the above compound in the preparation of anti-HBV drugs. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a benzamide hepatitis B virus (HBV) capsid protein inhibitor and a preparation method and application thereof. Background Art

[0002] Hepatitis B virus (HBV), referred to as HBV, is an infectious disease mainly caused by liver damage due to persistent HBV infection. Further development can cause complications such as liver metabolic disorders, liver failure, cirrhosis and liver cancer. At present, the anti-HBV drugs approved by the US FDA for clinical use mainly include polyethylene glycol interferon α (PEG-IFNα) and nucleotide analogs. PEG-IFNα mainly exerts its antiviral effect through immunomodulation. Since it is only effective for some patients and has varying degrees of side effects, its wide clinical application is limited. Nucleoside analogs inhibit HBV genome replication by competitively inhibiting the activity of viral polymerase, and ultimately achieve the effect of anti-HBV, but they cannot completely eliminate HBV in the body, require long-term medication, are prone to drug resistance, and have a high recurrence rate after discontinuation of medication. In clinical practice, the combined use of nucleoside analogs and interferons can significantly inhibit viral replication and improve the quality of life and life expectancy of patients, but it cannot completely cure HBV and requires long-term medication. Therefore, there is an urgent need to explore new treatment strategies and develop new antiviral drugs.

[0003] At present, with the continuous development of structural biology research on HBV capsid protein, HBV capsid protein has become a new target that has attracted much attention in the field of anti-HBV drug research. The capsid protein inhibitors currently under development can be divided into two categories: Type I capsid protein inhibitors interfere with the normal assembly of viral nucleocapsids, causing them to form various forms of non-capsid structures, such as heteroaryl dihydropyrimidines (Bay 41-4109 and GLS4, etc.); Type II capsid protein inhibitors promote the formation of empty capsids with "normal" structures but without pregenomic RNA (pgRNA), such as phenylacrylamides (AT-130, etc.) and benzenesulfonamides (JNJ-6379 and NVR3-778, etc.). Summary of the invention

[0004] In order to overcome the defects of the above-mentioned prior art, the present invention provides a benzamide HBV capsid protein inhibitor and a preparation method thereof. The present invention also provides the activity screening results of the above-mentioned compounds as non-nucleoside HBV inhibitors and their applications.

[0005] The technical solution of the present invention is as follows:

[0006] 1. Benzamide HBV capsid protein inhibitors

[0007] A benzamide HBV capsid protein inhibitor having a structure shown in the following general formula I or II:

[0008]

[0009] Wherein, Z is carbonyl, thiocarbonyl, or dicarbonyl;

[0010] M is carbonyl, thiocarbonyl;

[0011] L is C 2-3 alkenyl, styryl, 3-6 membered cycloalkyl, halogen substituted benzyl, 5 membered heteroaryl, halogen substituted phenyl, heteroatom substituted or unsubstituted C 1-3 Alkyl-substituted phenyl, 3-6-membered cycloalkylamino, heteroatom-substituted or unsubstituted C 2-5 Aliphatic amine, halogen-substituted aromatic amine, halogen-substituted aromatic amine, halogen-substituted benzylamine, heteroatom-substituted or unsubstituted C 1-4 Alkyl substituted benzyl;

[0012] W is C 3-5 Aliphatic amine, 5-6 membered cycloalkylamine, halogen-substituted aromatic amine, halogen-substituted alkyl aromatic amine, halogen-substituted benzylamine, halogen-substituted alkyl benzylamine;

[0013] R1 is a methyl group or a bromine atom;

[0014] R2 is a methyl group or a fluorine atom;

[0015] R3 is a hydrogen atom or a fluorine atom.

[0016] According to the preferred embodiment of the present invention, in the general formula I or II, Z is M is L is

[0017] W is R1 is -CH3 or Br, R2 is -CH3 or F, and R3 is H or F.

[0018] According to the present invention, the benzamide HBV capsid protein inhibitor is further preferably characterized by being one of the compounds having the following structure:

[0019]

[0020]

[0021] 2. Preparation method of benzamide HBV capsid protein inhibitor

[0022] The preparation method of the benzamide HBV capsid protein inhibitor is to use 2-bromo-4-fluorobenzoic acid, 2-methyl-4-fluorobenzoic acid and 2-bromo-6-fluorobenzoic acid as raw materials, and prepare the compound disclosed in the present invention through one of the following synthetic routes;

[0023] Synthesis route 1 is as follows:

[0024]

[0025] Reagents and conditions: (i) concentrated HNO3, concentrated H2SO4, 0℃, 12h, rt.; (ii) thionyl chloride, N,N-dimethylformamide, 6h, 80℃; (iii) acetonitrile, 3-fluoro-4-methylaniline or 3,4,5-trifluoroaniline, 6h, 60℃; (iv) Fe powder, NH4Cl, methanol, water, 12h, 90℃; (v) different types of acyl chlorides, pyridine, dichloromethane, 4h, rt.

[0026] The different types of acyl chlorides are selected from: 4-cyanobenzoyl chloride, 4-bromobenzoyl chloride, 4-methylbenzoyl chloride, 4-n-propylbenzoyl chloride, 2-thiophenecarbonyl chloride, (E)-phenylacryloyl chloride, 3,4,5-trifluorobenzoyl chloride, 4-trifluoromethylbenzoyl chloride, 3-methoxypropionyl chloride, 4-fluorobenzoyl chloride, 4-fluorophenylacetyl chloride, acryloyl chloride, 2-butenoyl chloride, cyclopropylcarbonyl chloride, cyclobutylcarbonyl chloride, cyclopentylcarbonyl chloride, and cyclohexylcarbonyl chloride.

[0027] Synthesis route 2 is as follows:

[0028]

[0029] Reagents and conditions: (i) phenyl chloroformate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0030] The different types of amines are selected from: 4-hydroxybenzylamine, 3,5-difluorobenzylamine, 3-methyl-4-fluorobenzylamine, 4-trifluoromethylbenzylamine, 4-fluorobenzylamine, 3-aminomethylpyridine, 3,4,5-trifluorobenzylamine, 3-pentylamine, isopropylamine, 3,4,5-trifluoroaniline, 4-tert-butylbenzylamine, 4-hydroxypiperidine, 4-trifluoromethylaniline, cyclopentylamine, 4-hydroxycyclohexylamine, and 4-methoxybenzylamine.

[0031] Synthesis route 3 is as follows:

[0032]

[0033] Reagents and conditions: (i) phenyl chlorothioate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0034] The different types of amines are selected from: isopropylamine, 4-fluorobenzylamine, 3,5-difluorobenzylamine, 3-methyl-4-fluorobenzylamine, cyclopropylamine, ethylamine, allylamine, 1,1,1-trifluoropropane-2-amine, 4-trifluoromethylbenzylamine, 4-aminomethylphenylboronic acid, and N-isopropylmethylamine.

[0035] Synthesis route 4 is as follows:

[0036]

[0037] Reagents and conditions: (i) ethyl oxalyl chloride, dichloromethane, 3 h, rt.; (ii) NaOH, methanol, water, 4 h, rt.; (iii) different types of amines, HATU, N,N-diisopropylethylamine, dichloromethane, 6 h, rt.

[0038] The different types of amines are selected from: isopropylamine, cyclopentylamine, 1-amino-2-methyl-2-propanol, and cyclopropylamine.

[0039] Synthesis route 5 is as follows:

[0040]

[0041] Reagents and conditions: (i) concentrated HNO3, concentrated H2SO4, 0℃, 12h, rt.; (ii) thionyl chloride, N,N-dimethylformamide, 6h, 80℃; (iii) acetonitrile, 3,4,5-trifluoroaniline, 6h, 60℃; (iv) Fe powder, NH4Cl, methanol, water, 12h, 90℃; (v) phenyl chloroformate, pyridine, dichloromethane, 6h, rt.; (vi) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4h, rt.

[0042] The different types of amines are selected from the group consisting of isopropylamine, cyclohexylamine, 3,4,5-trifluoroaniline, 4-trifluoromethylaniline, 3,4,5-trifluorobenzylamine, 4-trifluoromethylbenzylamine, 4-fluorobenzylamine, and 4-methoxybenzylamine.

[0043] Synthesis route 6 is as follows:

[0044]

[0045] Reagents and conditions: (i) phenyl chlorothioate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0046] The different types of amines are selected from: 3-pentylamine, cyclopentylamine, (S)-3-aminotetrahydrofuran, and cyclohexylamine.

[0047] R1, R2, R3, L, and W in the above routes are as described for the corresponding positions of the compounds of the above general formula I or II.

[0048] III. Application of benzamide HBV capsid protein inhibitors

[0049] The present invention discloses the anti-HBV activity screening results of benzamide HBV capsid protein inhibitors and their application as anti-HBV inhibitors. Experiments prove that the benzamide compounds of the present invention can be used as classic HBV non-nucleoside inhibitors.

[0050] As shown in Table 1, the lead compound NVR 3-778 was selected as the positive control, and the synthesized target compounds 6a-6s, 8a-8r, 10a-10h, 13a-13d, 20a-20h, and 22a-22d were evaluated for in vitro anti-HBV activity, and the in vitro cytotoxicity of the drugs was determined by the CCK-8 method; at the same time, the HBV DNA replication inhibitory activity of the drugs was determined by the quantitative PCR method.

[0051] The benzamide HBV capsid protein inhibitor of the present invention is a type of non-nucleoside HBV inhibitor with a novel structure and can be used as a lead compound for anti-HBV.

[0052] The benzamide HBV capsid protein inhibitor of the present invention can be used as a non-nucleoside HBV inhibitor, and specifically used as a HBV inhibitor to prepare anti-hepatitis B drugs.

[0053] An anti-HBV pharmaceutical composition comprises the benzamide HBV capsid protein inhibitor of the present invention and one or more pharmaceutically acceptable carriers or excipients.

[0054] The present invention discloses such benzamide HBV capsid protein inhibitors, their preparation methods, anti-HBV activity screening results and their first application as anti-HBV inhibitors. Experiments prove that benzamide HBV capsid protein inhibitors can be used as HBV inhibitors for preparing anti-hepatitis B drugs. DETAILED DESCRIPTION

[0055] The following examples are helpful for understanding the present invention, but they cannot limit the content of the present invention. In the following examples, the numbers of all target compounds are the same as above.

[0056] Synthesis Scheme 1

[0057]

[0058] Reagents and conditions: (i) concentrated HNO3, concentrated H2SO4, 0℃, 12h, rt.; (ii) thionyl chloride, N,N-dimethylformamide, 6h, 80℃; (iii) acetonitrile, 3-fluoro-4-methylaniline or 3,4,5-trifluoroaniline, 6h, 60℃; (iv) Fe powder, NH4Cl, methanol, water, 12h, 90℃; (v) different types of acyl chlorides, pyridine, dichloromethane, 4h, rt.

[0059] Example 1: Preparation of intermediate 2a: Take a 100 mL round-bottom flask, add 22.5 mL of concentrated H2SO4, add 22.83 mmol of 2-bromo-4-fluorobenzoic acid under ice bath, slowly add 2 mL of concentrated HNO3, and react at room temperature for 12 h. After the reaction, add dropwise 200 mL of ice water, filter, wash with water, and dry to obtain 4.2813 g of yellow-white solid, with a yield of 71%.

[0060] Example 2: Preparation of intermediate 2b. The operation is the same as that of Example 1, except that 2-bromo-4-fluorobenzoic acid is replaced by 2-methyl-4-fluorobenzoic acid.

[0061] Example 3: Preparation of intermediate 3a. Take a 50 ml round-bottom flask, dissolve 3.21 mmol of intermediate 2a in 10 mL of thionyl chloride, add 2 drops of N,N-dimethylformamide, reflux at 80°C, cool to room temperature after the reaction, and obtain an oily product after rotary evaporation.

[0062] Example 4: Preparation of intermediate 3b: The operation is the same as Example 3, except that the raw material 2a is replaced by 2b.

[0063] Example 5: Preparation of intermediate 4a. Take a 50 mL round-bottom flask, dissolve the intermediate 3a in 15 mL acetonitrile, add 3-methyl-4-fluoroaniline, reflux at 60°C, cool to room temperature after the reaction, concentrate, dry load, quickly prepare silica gel chromatography, and recrystallize using a dichloromethane-n-hexane mixed solvent.

[0064] Example 6: Preparation of intermediate 4b. The operation is the same as that of Example 5, except that 3-methyl-4-fluoroaniline is replaced by 3,4,5-trifluoroaniline.

[0065] Example 7: Preparation of intermediate 4c. The operation is the same as Example 5, except that the raw material 3a is replaced by 3b.

[0066] Example 8: Preparation of intermediate 5a: Take a 100 mL round-bottom flask, dissolve 5.39 mmol of intermediate 4a in a mixed solvent of methanol (10 mL) and water (10 mL), add 18.86 mmol Fe powder and 10.78 mmol NH4Cl, and reflux at 90° C. After the reaction is completed, use diatomaceous earth to filter while hot, concentrate the filtrate, and dry to obtain a white solid with a yield of 75%.

[0067] Example 9: Preparation of intermediate 5b: The operation is the same as Example 8, except that raw material 4a is replaced by 4b, to obtain a white solid with a yield of 72%.

[0068] Example 10: Preparation of intermediate 5c. The operation is the same as Example 8, except that the raw material 4a is replaced by 4c, to obtain a white solid with a yield of 69%.

[0069] Example 11: Preparation of compound 6a. Take a 50mL round-bottom flask, dissolve 1.03mmol 5a in 8mL dichloromethane, add 1.23mmol 4-cyanobenzoyl chloride, add 3.08mmol pyridine, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, remove dichloromethane by rotary evaporation, add 2N HCl solution for extraction, combine the organic phases, wash with saturated brine (20mL×3), dry with anhydrous sodium sulfate, concentrate, dry-load, separate by rapid preparative silica gel chromatography, and recrystallize to obtain the target compound. The product is a white solid with a yield of 62% and a melting point of 216.5-218.3℃. 1 H NMR (400MHz, DMSO-d6) δ10.60(s,1H),10.54(s,1H),8.13(d,J=8.0Hz,2H),8.05(d,J=8.1Hz,2H ),7.86–7.83(m,2H),7.66–7.63(m,1H),7.52–7.48(m,1H),7.13(t,J=9.2Hz,1H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.03,164.79,158.66,138.01,135.98,133.08,129.19,126.76,125.65,125.52,124.94,124.76,123 .09,123.04,121.09,120.86,119.40,119.32,118.71,116.20,115.63,115.41,114.82,14.87,14.84.ESI-MS:470.03271[M+H] + ,C 22 H 14 BrF2N3O2[469.02375].

[0070] Example 12: Preparation of compound 6b. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 4-bromobenzoyl chloride. The product is a white solid with a yield of 55% and a melting point of 210.5-212.8°C. 1H NMR(400MHz,DMSO-d6)δ10.53(s,1H),10.42(s,1H),7.94–7.91(m,2H),7.84–7.76(m,4H) ),7.65(d,J=7.1Hz,1H),7.50(dt,J=8.0,3.5Hz,1H),7.13(t,J=9.2Hz,1H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.14,165.08,158.67,154.64,135.88,135.32,133.11,132.07,130.47,126.78,126.43,125.80,124.94 ,124.76,123.10,123.05,121.05,120.81,119.41,119.33,115.94,115.85,115.64,115.41,14.88,14.85.ESI-MS:546.9269[M+Na] + ,C 26 H 21 F4N3O4S[523.93696].

[0071] Example 13: Preparation of compound 6c. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 4-methylbenzoyl chloride. The product is a white solid with a yield of 65% and a melting point of 215.5-217.1°C. 1 H NMR (400MHz, DMSO-d6) δ10.53(s,1H),10.23(s,1H),7.89(d,J=7.8Hz,2H),7.82–7.79(m,2H),7.65(d,J =7.0Hz,1H),7.52–7.48(m,1H),7.35(d,J=7.8Hz,2H),7.14(d,J=9.2Hz,1H),2.39(s,3H),2.24(s,3H). 13 C NMR (100MHz, DMSO-d6) δ165.81,165.12,156.27,142.69,135.82,135.78,135.32,135.30,131.16,129.53,128.38,126.74,126. 11,124.92,124.74,123.09,123.04,120.97,120.74,119.40,119.32,115.63,115.40,21.52,14.88,14.85.ESI-MS:457.038[MH] - ,C 22H 17 BrF2N2O2[458.04415].

[0072] Example 14: Preparation of compound 6d. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with 4-n-propylbenzoyl chloride. The product is a white solid with a yield of 59% and a melting point of 225.2-226.9°C. 1 H NMR (400MHz, DMSO-d6) δ10.53(s,1H),10.24(s,1H),7.91(d,J=6.5Hz,2H),7.82(q,J=3.3,2.1Hz,2H),7.66(d,J=6.1Hz,1H), 7.52–7.50(m,1H),7.37(d,J=7.8Hz,2H),7.14(s,1H),2.65(s,2H),2.25(s,3H),1.63(d,J=7.5Hz,2H),0.91(d,J=1.6Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ165.88,165.12,147.21,135.79,135.30,131.50,128.94,128.40,126.66,126.13,124.92,124.75,1 23.09,123.04,120.97,120.73,119.40,119.32,115.63,115.40,37.53,24.32,14.87,14.84,14.04.ESI-MS:487.08411[M+H] + ,C 24 H 21 BrF2N2O2[486.07545].

[0073] Example 15: Preparation of compound 6e. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with 2-thiophenecarbonyl chloride. The product is a light yellow solid with a yield of 55% and a melting point of 214.9-216.1°C. 1 H NMR (400MHz, DMSO-d6) δ10.54(s,1H),10.41(s,1H),8.06(d,J=3.7Hz,1H),7.90(d,J=5.0Hz,1H),7.80(dd,J=15.1,8. 8Hz,2H),7.65(d,J=7.1Hz,1H),7.50(dt,J=7.6,2.8Hz,1H),7.24(d,J=3.4Hz,1H),7.12(d,J=8.3Hz,1H),2.24(s,3H). 13C NMR(100MHz,DMSO-d6)δ165.04,160.46,157.21,156.27,138.98,135.90,135.86,135.32,135.29,132.96,130.61,128.74,126.96,125.60,125 .47,124.92,124.74,123.09,123.05,121.05,120.82,119.41,119.33, 115.94,115.85,115.62,115.39,14.88,14.85.ESI-MS:450.99308[M+H] + ,C 19 H 13 BrF2N2O2S[449.98492].

[0074] Example 16: Preparation of compound 6f. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by (E)-phenylacryloyl chloride. The product is a white solid with a yield of 57% and a melting point of 208.2-210.7°C. 1 H NMR (400MHz, DMSO-d6) δ10.51(s,1H),10.21(s,1H),8.39(d,J=7.9Hz,1H),7.80(d,J=10.3H z,1H),7.64(d,J=6.8Hz,4H),7.47(dd,J=15.9,7.8Hz,4H),7.16–7.09(m,2H),2.25(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.34,164.69,156.29,152.03,141.86,135.90,135.32,135.04,130.56,129.55,128.38,126.81,126.70 ,123.10,123.06,122.93,121.88,120.57,120.34,119.40,119.33,115.65,115.42,113.37,14.88,14.85.ESI-MS:493.0342[M+Na] + ,C 23 H 17 BrF2N2O2[470.04415].

[0075] Example 17: Preparation of compound 6g. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 3,4,5-trifluorobenzoyl chloride. The product is a white solid with a yield of 55% and a melting point of 217.5-219.4°C. 1H NMR (400MHz, DMSO-d6) δ10.55(d,J=5.2Hz,2H),7.95(t,J=7.5Hz,2H),7.86–7. 80(m,2H),7.65(d,J=7.0Hz,1H),7.52–7.48(m,1H),7.13(s,1H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ164.99,162.86,156.28,135.28,126.85,124.94,124.76,123.03,121.15,120.9 1,119.40,119.32,116.37,115.64,115.41,113.71,113.65,113.49,14.87,14.84.ESI-MS:499.009[M+H] + ,C 21 H 12 BrF5N2O2[498.00023].

[0076] Example 18: Preparation of compound 6h. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 4-trifluoromethylbenzoyl chloride. The product is a white solid with a yield of 55% and a melting point of 221.2-224.6°C. 1 H NMR (400MHz, DMSO-d6) δ10.59(s,1H),10.54(s,1H),8.17(d,J=8.0Hz,2H),7.94(d,J=8.1Hz,2H),7.85(d d,J=8.6,3.3Hz,2H),7.65(dd,J=7.1,2.6Hz,1H),7.52–7.47(m,1H),7.13(t,J=9.2Hz,1H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.06,164.99,158.68,156.29,137.84,135.98,135.32,135.29,126.79,126.06,126.02,124.95,12 4.77,123.10,123.05,121.10,120.86,119.41,119.33,116.14,116.05,115.65,115.42,14.87,14.84.ESI-MS:513.0228[M+H] + ,512.01588.

[0077] Example 19: Preparation of compound 6i. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 3-methoxypropionyl chloride. The product is a white solid with a yield of 63% and a melting point of 218.3-220.5°C. 1 H NMR (400MHz, DMSO-d6) δ10.47(s,1H),9.99(s,1H),8.18(d,J=7.9Hz,1H),7.75(dd,J=10.5,1.5Hz,1H),7.63(d,J=7.0Hz,1 H),7.50–7.47(m,1H),7.12(t,J=9.2Hz,1H),3.63–3.59(m,2H),3.24(d,J=1.5Hz,3H),2.66(t,J=6.1Hz,2H),2.24(s,3H). 13 C NMR (101MHz, DMSO-d6) δ170.60,165.28,158.65,135.78,135.28,135.25,126.53,126.41,124.92,124.74,123.29,123. 10,123.05,120.53,120.30,119.40,119.32,115.61,115.38,68.43,58.43,36.86,14.86,14.83.ESI-MS:427.047[M+H] + ,C 18 H 17 BrF2N2O3[426.03906].

[0078] Example 20: Preparation of compound 6j. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by 4-fluorobenzoyl chloride. The product is a white solid with a yield of 55% and a melting point of 217.2-218.5°C. 1 H NMR (400MHz, DMSO-d6) δ8.77(d,J=4.4Hz,1H),8.54(d,J=8.4Hz,1H),8.04–7.99(m,4H),7.52(ddd,J=8.6,4.5,1.5Hz,1H),7.32(td,J=8.8,1.6Hz,4H). 13 C NMR(101MHz,DMSO-d6)δ166.84,166.63,164.14,151.59,140.09,135.11,132.62,132.53 ,131.09,129.34,127.83,127.80,121.20,116.20,115.98,14.83.ESI-MS:463.0268[M+H] +,C 21 H 14 BrF3N2O2[462.01907].

[0079] Example 21: Preparation of compound 6k. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with 4-fluorophenylacetyl chloride. The product is a white solid with a yield of 62% and a melting point of 224.9-225.3°C. 1 H NMR (400MHz, DMSO-d6) δ10.47(s,1H),10.24(s,1H),8.14(d,J=7.7Hz,1H),7.77(d,J=10.1Hz,1H),7.62(d,J=6. 9Hz,1H),7.48(dd,J=9.3,4.6Hz,1H),7.40–7.35(m,2H),7.15(dd,J=15.0,8.7Hz,3H),3.77(s,2H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ170.36,165.21,162.83,160.42,156.26,152.34,135.80,135.26,132.21,131.56,131.48,126.44,126.33,1 24.92,124.74,123.51,123.09,123.04,120.62,120.38,119.39,119.31,115.62,115.41,42.02,14.86,14.83.ESI-MS:477.042[M+H] + ,C 22 H 16 BrF3N2O2[476.03472].

[0080] Example 22: Preparation of compound 61. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by acryloyl chloride. The product is a white solid with a yield of 57% and a melting point of 214.2-216.3°C. 1 H NMR (400MHz, DMSO-d6) δ10.50(s,1H),10.22(s,1H),8.27(d,J=7.9Hz,1H),7.80(d,J=10.3Hz,1H),7.64(d,J=6.1Hz,1H),7.50 (dd,J=8.6,4.1Hz,1H),7.15(d,J=9.2Hz,1H),6.68–6.61(m,1H),6.31(d,J=17.0Hz,1H),5.83(d,J=10.2Hz,1H),2.24(s,3H). 13C NMR(100MHz,DMSO-d6)δ165.24,164.21,158.65,156.26,152.31,135.86,135.82,135.29,135.26,131.42,128.70,126.40,126.29,12 4.94,124.76,123.46,123.07,123.03,120.63,120.40,119.38,119.30,115.64,115.40,113.88,14.88,14.84.ESI-MS:395.020[M+H] + ,C 17 H 13 BrF2N2O2[394.01285].

[0081] Example 23: Preparation of compound 6m. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with 2-butenoyl chloride. The product is a white solid with a yield of 57% and a melting point of 215.6-216.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.54(s,1H),10.04(s,1H),8.31(d,J=7.9Hz,1H),7.81(d,J=10.4Hz,1H),7.69(dd,J=7.1,2.5Hz,1H),7 .56–7.52(m,1H),7.19(d,J=9.2Hz,1H),6.90(dd,J=15.0,7.3Hz,1H),6.39(d,J=15.3Hz,1H),2.29(s,3H),1.92(d,J=6.9Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ165.29,164.47,154.72,141.96,135.80,135.76,135.30,135.27,126.69,126.58,125.57,124.93,124.75,1 23.34,123.07,123.02,120.52,120.29,119.37,119.29,115.63,115.40,113.43,113.34,18.12,14.87,14.84.ESI-MS:409.036[M+H] + ,C 18 H 15 BrF2N2O2[408.02850].

[0082] Example 24: Preparation of compound 6n. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with cyclopropylcarbonyl chloride. The product is a white solid with a yield of 66% and a melting point of 213.2-215.7°C. 1 H NMR (600MHz, DMSO-d6) δ10.46(s,1H),10.26(s,1H),8.18(d,J=8.0Hz,1H),7.76(d,J=10.4Hz,1H),7.64–7.62(m ,1H),7.49–7.47(m,1H),7.13(d,J=9.2Hz,1H),2.24(d,J=1.9Hz,3H),2.04(t,J=5.2Hz,1H),0.84–0.82(m,4H). 13 C NMR(150MHz,DMSO-d6)δ173.04,165.28,158.23,156.64,154.09,152.42,135.73,135.70,135.28,135.27,126.65,126.57,124.88, 124.77,123.36,123.05,123.02,120.47,120.32,119.35,119.30,115.58,115.42,14.87,14.85,14.55,8.26.ESI-MS:409.036[M+H] + ,C 18 H 15 BrF2N2O2[408.02850].

[0083] Example 25: Preparation of compound 6o. The operation is the same as that of Example 11, except that 4-cyanobenzoyl chloride is replaced with cyclobutylcarbonyl chloride. The product is a white solid with a yield of 62% and a melting point of 218.2-220.8°C. 1 H NMR (600MHz, DMSO-d6) δ10.48(s,1H),9.79(s,1H),8.15(d,J=7.9Hz,1H),7.74(d,J=10.3Hz,1H),7.65–7.63(m,1H),7.50–7.48(m,1H),7.12(d,J =9.1Hz,1H),3.41–3.38(m,1H),2.24(d,J=1.9Hz,3H),2.22–2.18(m,2H) ,2.12(dt,J=7.7,3.4Hz,2H),1.94(d,J=10.8Hz,1H),1.84–1.80(m,1H). 13C NMR (150MHz, DMSO-d6) δ174.13,165.28,156.64,154.52,135.73,135.70,135.29,135.27,126.60,126.52,124.89,124.77,123. 74,123.06,123.03,120.50,120.35,119.36,119.31,115.58,115.43,113.37,25.04,18.20,14.87,14.85.ESI-MS:423.051[M+H] + ,C 19 H 17 BrF2N2O2[422.04415].

[0084] Example 26: Preparation of compound 6p. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced with cyclopentylcarbonyl chloride. The product is a white solid with a yield of 65% and a melting point of 224.3-225.2°C. 1 H NMR (600MHz, DMSO-d6) δ10.47(s,1H),9.90(s,1H),8.13(d,J=8.0Hz,1H),7.74(d,J=10.3Hz,1H),7.64–7.62(m,1H),7.50–7.48(m ,1H),7.13(t,J=9.2Hz,1H),2.97–2.94(m,1H),2.24(d,J=1.9Hz,3H),1.85(p,J=3.7Hz,2H),1.73–1.66(m,4H),1.57–1.54(m,2H). 13 C NMR (150MHz, DMSO-d6) δ175.73,165.28,158.23,156.64,152.84,135.71,135.68,135.27,126.67,126.59,124.88,124.76,123.79,123. 06,123.04,120.50,120.34,119.36,119.31,115.57,115.42,113.42,113.36,45.00,30.57,26.19,14.87,14.85.ESI-MS:437.067[M+H] + ,C 20 H 19 BrF2N2O2[436.05980].

[0085] Example 27: Preparation of compound 6q. The operation is the same as Example 11, except that 4-cyanobenzoyl chloride is replaced by cyclohexylcarbonyl chloride. The product is a white solid with a yield of 61% and a melting point of 228.3-229.2°C. 1 H NMR(400MHz,DMSO-d6)δ10.47(s,1H),9.86(s,1H),8.14–8.12(m,1H),7.76 –7.73(m,1H),7.64(t,J=3.6Hz,1H),7.49(dt,J=4.4,2.3Hz,1H),7.13(s,1H ),2.54(d,J=11.6Hz,1H),2.24(d,J=1.8Hz,3H),1.76(dt,J=8.8,4.4Hz,4H) ,1.65(d,J=11.4Hz,2H),1.39(d,J=11.0Hz,2H),1.26(q,J=4.6,2.9Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ175.52,165.28,135.70,135.66,135.27,126.70,126.58,124.91,123.66,123.06,123.02,120 .52,120.29,119.37,119.29,115.62,115.39,113.29,44.53,29.56,25.82,25.59,14.88,14.85.ESI-MS:451.083[M+H] + ,C 21 H 21 BrF2N2O2[450.07545].

[0086] Example 28: Preparation of compound 6r. The operation is the same as Example 12, except that the raw material 5a is replaced by 5b. The product is a white solid with a yield of 51% and a melting point of 225.5-227.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 10.46 (s, 1H), 7.93 (d, J = 8.1Hz, 1H), 7.88 ( s,2H),7.78(d,J=8.2Hz,2H),7.72(d,J=8.2Hz,1H),7.62(dd,J=10.2,6.4Hz,2H). 13C NMR(100MHz,DMSO-d6)δ165.61,165.14,154.87,135.10,133.02,132.18,132.07,131.77,130.46,126 .93,126.47,126.02,125.90,121.24,121.00,115.89,115.80,104.52,104.28.ESI-MS:546.910[M+H] + ,C 20 H 10 Br2F4N2O2[545.90247].

[0087] Example 29: Preparation of compound 6s. The operation is the same as 13, except that the raw material 5a is replaced by 5b. A white solid is obtained with a yield of 56% and a melting point of 220.3-223.1°C. 1 H NMR (400MHz, DMSO-d6) δ10.95(s,1H),10.26(s,1H),7.89(s,2H),7.85(d,J=9.8Hz,2H),7.64–7.60(m,2H),7.36(d,J=7.8Hz,2H),2.40(s,3H). 13 CNMR(100MHz,DMSO-d6)δ165.83,165.66,157.43,154.89,142.74,134.98,131.10,129.53,12 8.38,126.90,126.36,126.24,121.17,120.93,104.53,104.29,21.52.ESI-MS:481.018[M+H] + ,C 21 H 13 BrF4N2O3[480.00965].

[0088] Synthesis Scheme 2

[0089]

[0090] Reagents and conditions: (i) phenyl chloroformate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0091] Example 30: Preparation of intermediate 7a. Take a 50mL round-bottom flask, dissolve 2.93mmol 5a in 10mL dichloromethane, add 3.52mmol phenyl chloroformate, add 8.79mmol pyridine, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, remove dichloromethane by rotary evaporation, add 2N HCl solution for extraction, combine the organic phases, wash with saturated brine (20mL×3), dry with anhydrous sodium sulfate, concentrate, dry-load, separate by rapid preparative silica gel chromatography, and recrystallize to obtain the target compound. The product is a white solid with a yield of 65% and a melting point of 224.5-226.3℃.

[0092] Example 31: Preparation of intermediate 7b. The operation is the same as 30, except that raw material 5a is replaced by 5b. White solid is obtained. Yield: 56%, melting point 228.1-229.9℃.

[0093] Example 32: Preparation of compound 8a: Take a 50 mL round-bottom flask, dissolve 1.08 mmol 7a in 8 mL dichloromethane, add 1.30 mmol 4-hydroxybenzylamine, add 1.63 mmol N, N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel column for separation, and recrystallize from a dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 52% and a melting point of 245.5-246.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.43(s,1H),9.32(s,1H),8.61(s,1H),8.39(d,J=8.2Hz,1H),7.67–7.62(m,2H),7.51 –7.47(m,1H),7.13–7.09(m,3H),7.03(t,J=5.8Hz,1H),6.74–6.71(m,2H),4.18(d,J=5.5Hz,2H),2.24(s,3H). 13 CNMR(100MHz,DMSO-d6)δ165.68,156.87,156.25,154.97,135.82,135.79,135.35,130.19,129.13,128.59,12 4.91,124.73,123.10,123.06,119.79,119.40,119.32,115.61,115.38,56.51,19.03.ESI-MS:512.0406[M+Na] + ,C 22 H 18 BrF2N3O3[489.04996].

[0094] Example 33: Preparation of compound 8b, same as Example 32, except that 4-hydroxybenzylamine was replaced with 3,5-difluorobenzylamine to obtain a white solid with a yield of 49% and a melting point of 236.2-238.9°C. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.79(d,J=2.6Hz,1H),8.34(d,J=8.3Hz,1H),7.68(d,J=10.8Hz,1H),7.64–7.61(m,1 H),7.50–7.46(m,1H),7.25(t,J=6.1Hz,1H),7.14–7.08(m,2H),7.01(d,J=7.6Hz,2H),4.35(d,J=6.0Hz,2H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.59,164.17,164.04,161.59,155.17,145.42,135.82,135.32,135.29,128.46,128.35,124.88 ,124.71,123.08,123.04,119.38,115.58,115.35,110.53,110.28,102.65,42.57,14.85,14.83.ESI-MS:510.04529[M+H] + ,C 22 H 16 BrF4N3O2[509.03620].

[0095] Example 34: Preparation of compound 8c. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 3-methyl-4-fluorobenzylamine to give a white solid. Yield: 53%, melting point: 233.2-235.9°C. 1 H NMR (400MHz, DMSO-d6) δ10.43(s,1H),8.67(s,1H),8.37(d,J=8.3Hz,1H),7.67–7.62(m,2H),7.49(dd,J=8.6,4.0Hz ,1H),7.20(d,J=7.9Hz,1H),7.13(d,J=10.0Hz,3H),7.10–7.06(m,1H),4.26(d,J=5.7Hz,2H),2.23(d,J=5.4Hz,6H). 13C NMR(100MHz,DMSO-d6)δ165.64,158.61,155.03,152.86,136.07,135.79,135 .34,135.31,130.93,130.88,129.83,128.60,126.94,126.86,124.89,124.7 1,124.55,124.38,123.08,123.03,119.81,119.37,119.29,115.69,115.59, 115.35,115.13,109.60,55.38,48.10,42.57,21.13.ESI-MS:506.06995[M+H] + ,C 23 H 19 BrF3N3O2[505.06127].

[0096] Example 35: Preparation of compound 8d. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-trifluoromethylbenzylamine to give a white solid. Yield: 49%, melting point: 238.2-239.5°C. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.78(s,1H),8.35(d,J=8.0Hz,1H),7.71(d,J=8.0Hz,2H),7.67(d,J=10.8Hz,1H),7.64–7.60 (m,1H),7.52(d,J=8.1Hz,2H),7.50–7.46(m,1H),7.28(t,J=6.0Hz,1H),7.11(t,J=9.2Hz,1H),4.42(d,J=5.8Hz,2H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.63,158.63,156.24,155.21,150.50,145.37,135.81,135.33,128.51,128.40,128.20,127.84,126.19,125.7 6,125.72,123.10,123.05,119.87,119.77,119.64,119.39,119.31,115.60,115.37,55.38,42.85,14.86,14.82.ESI-MS:564.0378[M+Na] + ,C 23 H 17 BrF5N3O2[541.04243].

[0097] Example 36: Preparation of compound 8e. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-fluorobenzylamine to give a white solid. Yield: 54%, melting point: 231.3-232.6°C. 1 H NMR (400MHz, DMSO-d6) δ10.43(s,1H),8.69(s,1H),8.37(d,J=8.1Hz,1H),7.66(d,J=10.8Hz,1H),7.63(d,J=7.4Hz, 1H),7.48(dt,J=7.9,3.5Hz,1H),7.34(dd,J=8.2,5.6Hz,2H),7.19–7.09(m,4H),4.30(d,J=5.7Hz,2H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.63,162.89,158.61,156.23,155.08,136.49,136.46,135.82,135.79,135.33,135.31,129.68,129.60,128.57,12 8.47,124.90,124.72,123.08,123.04,119.83,119.66,119.60,119.38 ,119.30,115.68,115.47,42.53,14.86,14.83.ESI-MS:514.0361[M+Na] + ,C 22 H 17 BrF3N3O2[491.04562].

[0098] Example 37: Preparation of compound 8f. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 3-aminomethylpyridine to give a white solid. Yield: 54%, melting point: 235.5-236.8°C. 1 H NMR (400MHz, DMSO-d6) δ10.43(s,1H),8.74(s,1H),8.53(s,1H),8.47(d,J=4.5Hz,1H),8.35(d,J=8.3Hz,1H),7.74–7.62(m,3H), 7.52–7.46(m,1H),7.37(dd,J=7.9,4.8Hz,1H),7.23(t,J=6.0Hz,1H),7.12(t,J=9.1Hz,1H),4.35(d,J=5.8Hz,2H),2.24(s,3H). 13C NMR(100MHz,DMSO-d6)δ165.63,155.18,149.19,148.67,135.80,135.52,135.33,124.91,124.73,124.01,123.11 ,123.06,119.88,119.79,119.65,119.40,119.32,115.61,115.38,40.97,14.86,14.83.ESI-MS:497.0408[M+Na] + ,C 21 H 17 BrF2N4O2[474.05029].

[0099] Example 38: Preparation of compound 8g. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 3,4,5-trifluorobenzylamine to give a white solid. Yield: 51%, melting point: 237.2-238.5°C. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.79(s,1H),8.32(d,J=8.3Hz,1H),7.68(d,J=10.8Hz,1H),7.62(dd,J=7.2,2.5Hz ,1H),7.48(dd,J=8.6,4.0Hz,1H),7.24(dd,J=9.4,6.7Hz,3H),7.12(t,J=9.2Hz,1H),4.31(d,J=5.9Hz,2H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.61,158.63,155.17,150.59,138.13,135.84,135.33,128.43,128.33,124.90,124.72,123.09,123.04,119.90 ,119.67,119.39,119.31,115.60,115.38,111.99,111.94,111.83,111.78,109.93,109.84,42.24,14.86,14.83.ESI-MS:550.0128[M+Na] + ,C 22 H 15 BrF5N3O2[527.02678].

[0100] Example 39: Preparation of compound 8h. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 3-pentylamine to give a white solid. Yield: 58%, melting point: 227.3-228.7°C. 1H NMR (400MHz, DMSO-d6) δ10.41(s,1H),8.48(s,1H),8.40(d,J=8.3Hz,1H),7.66–7.62(m,2H),7.51–7.47(m,1H),7.1 3(d,J=9.1Hz,1H),6.54(d,J=8.5Hz,1H),4.36(d,J=1.5Hz,1H),2.23(s,3H),1.08–1.04(m,4H),0.87–0.83(m,6H). 13 CNMR(100MHz,DMSO-d6)δ165.72,154.89,135.80,135.36,128.78,124.90,124.72,123.09,123.05,119.72 ,119.49,119.39,119.31,119.20,115.60,115.37,56.51,27.43,19.03,10.56.ESI-MS:452.07928[MH]-,C 20 H 22 BrF2N3O2[453.08635].

[0101] Example 40: Preparation of compound 8i. Same as Example 32, except that 4-hydroxybenzylamine was replaced with isopropylamine to give a white solid. Yield: 58%, melting point: 226.3-227.5°C. 1 H NMR (400MHz, DMSO-d6) δ10.41(s,1H),8.42(s,1H),8.38(d,J=8.3Hz,1H),7.64(t,J=7.9Hz,2H),7.48(dt,J=6.9,3.1 Hz,1H),7.12(t,J=9.2Hz,1H),6.62(d,J=7.3Hz,1H),3.74(q,J=6.6Hz,1H),2.23(s,3H),1.10(dd,J=6.5,1.6Hz,6H). 13 C NMR(100MHz,DMSO-d6)δ165.70,154.28,135.80,135.37,135.33,128.78,128.67,124.90,124.72,123.08,123.04,11 9.73,119.50,119.38,119.31,115.61,115.38,109.20,109.10,41.58,23.27,14.87,14.84.ESI-MS:448.0464[M+Na] + ,C 18 H 18BrF2N3O2[425.05505].

[0102] Example 41: Preparation of compound 8j. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 3,4,5-trifluoroaniline to give a white solid. Yield: 52%, melting point: 236.2-237.3°C. 1 H NMR (400MHz, DMSO-d6) δ10.48(s,1H),9.43(s,1H),8.97(s,1H),8.29(d,J=8.2Hz,1H),7.75(d,J=10.7Hz,1H),7. 64(d,J=6.9Hz,1H),7.50(dt,J=7.9,3.3Hz,1H),7.38(dd,J=10.6,6.2Hz,2H),7.13(t,J=9.2Hz,1H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ165.44,156.28,152.35,136.01,135.97,135.30,127.35,127.24,124.94,124.76,123.11,123 .07,120.64,120.18,119.95,119.41,119.33,115.63,115.40,111.43,111.34,14.87,14.83.ESI-MS:536.0032[M+Na] + ,C 21 H 13 BrF5N3O2[513.01113].

[0103] Example 42: Preparation of compound 8k. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-tert-butylbenzylamine to give a white solid. Yield: 55%, melting point: 235.5-236.8°C. 1 H NMR (400MHz, DMSO-d6) δ10.43(s,1H),8.66(s,1H),8.40(s,1H),7.65(t,J=9.9Hz,3H),7.49(d,J=4.7Hz ,1H),7.36(d,J=6.7Hz,2H),7.24(s,2H),7.12(s,2H),4.27(s,2H),2.24(s,3H),1.27(d,J=1.5Hz,9H). 13C NMR (100MHz, DMSO-d6) δ165.64,155.03,152.82,149.82,137.12,135.79,135.34,127.51,125.61,124.89,123. 08,119.80,119.57,119.29,115.59,115.36,48.05,42.98,34.64,31.63,14.87,14.84.ESI-MS:530.12647[M+H] + ,C 26 H 26 BrF2N3O2[529.11765].

[0104] Example 43: Preparation of compound 81, same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-hydroxypiperidine to give a white solid with a yield of 57% and a melting point of 225.5-226.7°C. 1 H NMR (400MHz, DMSO-d6) δ10.46(s,1H),8.51(s,1H),7.68–7.62(m,3H),7.51–7.47(m,1H),7.13(t,J=9.2Hz,1H),4.75(d,J=3.7Hz,1H),3.80(d ,J=13.7Hz,2H),3.68(dq,J=8.9,4.4Hz,1H),3.08(td,J=11.3,10.5,5.2Hz,2H),2.24(s,3H),1.78–1.72(m,2H),1.35(dd,J=11.4,7.7Hz,2H). 13 C NMR (100MHz, DMSO-d6) δ165.37,156.25,154.92,135.41,135.36,128.41,128.30,125.38,124.90,124.72,123.08,123. 03,120.49,120.25,119.38,119.31,115.61,115.38,113.02,66.20,42.20,34.59,14.87,14.84.ESI-MS:466.05905[MH] - ,C 20 H 20 BrF2N3O3[467.06561].

[0105] Example 44: Preparation of compound 8m. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-trifluoromethylaniline to give a white solid. Yield: 47%, melting point: 237.5-239.2°C. 1H NMR (400MHz, DMSO-d6) δ10.49(s,1H),9.53(s,1H),8.93(d,J=2.4Hz,1H),8.35(d,J=8.2Hz, 1H),7.66(s,6H),7.50(dt,J=7.4,3.5Hz,1H),7.13(t,J=9.2Hz,1H),2.24(d,J=1.8Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ165.47,152.29,143.28,135.32,126.72,124.93,124.75,123 .13,120.35,119.42,119.35,118.47,115.64,115.40,19.13.ESI-MS:550.0153[M+Na] + ,C 22 H 15 BrF5N3O2[527.02678].

[0106] Example 45: Preparation of compound 8n: Same as Example 32, except that 4-hydroxybenzylamine was replaced with cyclopentylamine to give a white solid with a yield of 62% and a melting point of 225.9-226.5°C. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.43–8.37(m,2H),7.64(dd,J=9.6,5.8Hz,2H),7.49(dt,J=7.5,3.4Hz,1H),7.13(t,J=9.2Hz,1H),6.77 (d,J=7.0Hz,1H),3.93(q,J=6.5Hz,1H),2.24(s,3H),1.84(dd,J=12.7,6.2Hz,2H),1.59(dq,J=25.1,7.6Hz,4H),1.37(dd,J=12.7,6.3Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ165.70,154.53,135.77,135.36,128.78,128.67,124.90,124.72,123.08,123.04,1 19.73,119.50,119.38,119.30,115.61,115.38,51.41,33.20,23.56,14.87,14.84.ESI-MS:450.06363[MH] - ,C 20 H 20 BrF2N3O2[451.07070].

[0107] Example 46: Preparation of compound 8o: Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-hydroxycyclohexylamine to give a white solid with a yield of 60% and a melting point of 228.5-229.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.45(s,1H),8.38(d,J=8.1Hz,1H),7.64(t,J=7.9Hz,2H),7.49(dd,J=8.0,3.6Hz,1H),7.13(t,J=9 .1Hz,1H),6.65(d,J=7.4Hz,1H),4.55(d,J=4.3Hz,1H),2.24(s,3H),1.88–1.78(m,4H),1.21(dq,J=20.1,11.6Hz,5H),0.97–0.91(m,1H). 13 C NMR(100MHz,DMSO-d6)δ165.70,154.33,152.72,135.75,135.35,135.33,128.63,124.91,124.73,123.08,123.03, 119.74,119.52,119.38,119.30,115.61,115.38,68.28,48.15,39.35,34.01,30.92,14.84.ESI-MS:480.0741[MH] - ,C 21 H 22 BrF2N3O3[481.08126].

[0108] Example 47: Preparation of compound 8p. Same as Example 32, except that 4-hydroxybenzylamine was replaced with 4-methoxybenzylamine to give a white solid. Yield: 52%, melting point: 213.5-214.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.44(s,1H),8.64(s,1H),8.39(d,J=8.3Hz,1H),7.65(s,2H),7.51–7.48(m,1H),7.23( d,J=8.1Hz,2H),7.15–7.09(m,2H),6.92–6.90(m,2H),4.24(d,J=4.9Hz,2H),3.74(d,J=1.5Hz,3H),2.24(s,3H). 13C NMR(100MHz,DMSO-d6)δ165.65,158.78,158.61,156.23,155.00,135.78,135.34,132.05,129.06,128.65,128.55,124.90,1 24.72,123.08,123.04,119.80,119.57,119.38,119.29,115.60,115.37,114.27,55.54,42.73,19.03.ESI-MS:504.073[M+H] + ,C 23 H 20 BrF2N3O3[503.06561].

[0109] Example 48: Preparation of compound 8q. Same as Example 35, raw material 7a was converted into 7b to obtain a white solid. Yield: 48%, melting point: 230.5-232.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.85(s,1H),8.83(s,1H),8.39(d,J=8.2Hz,1H),7.71(d,J=7.4Hz, 3H),7.62–7.58(m,2H),7.52(d,J=7.9Hz,2H),7.29(t,J=5.8Hz,1H),4.42(d,J=5.0Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ166.14,155.17,145.32,128.53,128.18,127.83,126.16,125.78,12 5.74,125.70,125.66,120.08,119.85,119.77,104.49,104.24,42.86.ESI-MS:564.017[M+H] + ,C 22 H 13 BrF7N3O2[563.00794].

[0110] Example 49: Preparation of compound 8r. Same as Example 36, raw material 7a was converted into 7b to obtain a white solid. Yield: 56%, melting point: 238.5-240.4°C. 1H NMR (400MHz, DMSO-d6) δ10.86(s,1H),8.74(s,1H),8.40(d,J=7.9Hz,1H),7.71(d,J=10.7H z,1H),7.63–7.58(m,2H),7.36–7.32(m,2H),7.17(t,J=8.1Hz,3H),4.30(d,J=5.3Hz,2H). 13 C NMR(100MHz,DMSO-d6)δ166.17,162.89,155.06,136.46,136.43,129.67,129.59,120.05 ,119.82,119.66,115.68,115.47,109.47,104.49,104.24,42.53.ESI-MS:514.020[M+H] + ,C 21 H 13 BrF5N3O2[513.01113].

[0111] Synthesis Scheme 3

[0112]

[0113] Reagents and conditions: (i) phenyl chlorothioate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0114] Example 50: Preparation of intermediate 9a: Take a 50mL round-bottom flask, dissolve 2.93mmol 5a in 10mL dichloromethane, add 3.52mmol phenyl chlorothioformate, add 8.79mmol pyridine, and stir at room temperature. TLC monitors the reaction. After the reaction is complete, remove dichloromethane by rotary evaporation, add 2N HCl solution for extraction, combine the organic phases, wash with saturated brine (20mL×3), dry with anhydrous sodium sulfate, concentrate, dry sample, separate by rapid preparative silica gel chromatography, and recrystallize with dichloromethane solvent. The product is a yellow solid with a yield of 61% and a melting point of 230.4-232.9°C.

[0115] Example 51: Preparation of intermediate 9b. The operation is the same as 50, except that raw material 5a is replaced by 5b. A yellow solid is obtained with a yield of 65% and a melting point of 235.1-238.0°C.

[0116] Example 52: Preparation of intermediate 9c. The operation is the same as 50, except that the raw material 5a is replaced by 5c. A yellow solid is obtained with a yield of 54% and a melting point of 231.5-232.8°C.

[0117] Example 53: Preparation of compound 10a: Take a 50 mL round-bottom flask, dissolve 1.05 mmol 9a in 8 mL dichloromethane, add 1.26 mmol 4-hydroxybenzylamine, add 1.57 mmol N,N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel column for separation, and recrystallize from dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 61% and a melting point of 238.5-239.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.46(s,1H),9.20(s,1H),8.14(s,1H),8.09–8.04(m,1H),7.72(d,J=9.4Hz,1H),7.65(d,J=6. 8Hz,1H),7.51–7.48(m,1H),7.13(s,1H),4.39–4.34(m,1H),2.24(s,3H),1.18(d,J=1.6Hz,3H),1.17(d,J=1.6Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ180.09,165.17,158.62,135.33,135.27,135.23,124.90,124.72,123.08,1 23.03,120.58,120.34,119.38,119.30,115.60,115.37,22.31,14.87,14.84.ESI-MS:442.040[M+H] + ,C 18 H 18 BrF2N3OS[441.03220].

[0118] Example 54: Preparation of compound 10b. The operation is the same as 53, except that isopropylamine is replaced by 4-fluorobenzylamine to obtain a white solid. Yield: 50%, melting point: 246.1-247.7°C. 1 H NMR (400MHz, DMSO-d6) δ10.47(s,1H),9.53(s,1H),8.55(s,1H),8.00(d,J=7.9Hz,1H),7.75(d,J=9.9Hz,1H),7.65( s,1H),7.51–7.48(m,1H),7.39(d,J=2.4Hz,2H),7.19(s,1H),7.14(d,J=9.2Hz,2H),4.74–4.71(m,2H),2.24(s,3H). 13C NMR(100MHz,DMSO-d6)δ181.91,165.06,158.64,156.26,135.43,135.28,130.00,129.92,124.91,124.73,123.10,1 23.05,120.85,120.62,119.40,119.33,115.68,115.62,115.41,115.38,47.18,14.87,14.84.ESI-MS:508.031[M+H] + ,C 22 H 17 BrF3N3OS[507.02278].

[0119] Example 55: Preparation of compound 10c. The operation is the same as 53, except that isopropylamine is replaced with 3,5-difluorobenzylamine to obtain a white solid. Yield: 55%, melting point: 249.5-250.9°C. 1 H NMR (600MHz, DMSO-d6) δ10.48(s,1H),9.67(s,1H),8.58(s,1H),7.92(d,J=7.8Hz,1H),7.77(d,J=9.9Hz,1H),7.65– 7.64(m,1H),7.51–7.49(m,1H),7.14–7.11(m,2H),7.05–7.03(m,2H),4.77(d,J=5.0Hz,2H),2.24(d,J=1.9Hz,3H). 13 C NMR(150MHz,DMSO-d6)δ182.41,165.01,163.65,163.56,162.02,161.93,158 .23,156.64,135.61,135.59,135.30,135.29,124.87,124.75,123.08,123.0 5,120.98,120.82,119.39,119.34,115.57,115.41,110.72,110.69,110.59, 110.56,102.89,102.72,102.55,47.11,14.87,14.85.ESI-MS:526.022[M+H] + ,C 22 H 16 BrF4N3OS[525.01336].

[0120] Example 56: Preparation of compound 10d. The operation is the same as 53, except that isopropylamine is replaced with 3-methyl-4-fluorobenzylamine to obtain a white solid. Yield: 52%, melting point: 245.1-247.7°C.1 H NMR (600MHz, DMSO-d6) δ10.47(s,1H),9.51(s,1H),8.53(s,1H),8.02(d,J=7.9Hz,1H),7.75(d,J=10.0Hz,1H),7.65–7.64(m,1H),7.51–7.48(m ,1H),7.26–7.24(m,1H),7.20(q,J=3.0Hz,1H),7.12(dd,J=8.8,7.2Hz,2H),4.68(d,J=5.0Hz,2H),2.24(d,J=1.9Hz,3H),2.22(d,J=1.8Hz,3H). 13 C NMR(150MHz,DMSO-d6)δ181.80,165.07,159.47,135.45,135.42,135.31,13 5.30,134.86,131.23,131.20,127.30,127.24,127.18,124.88,124.76,124. 45,124.34,123.06,123.03,120.80,120.64,119.36,119.31,115.57,115.4 2,115.26,115.12,47.27,14.87,14.85,14.68,14.66.ESI-MS:522.047[M+H] + ,C 23 H 19 BrF3N3OS[521.03843].

[0121] Example 57: Preparation of compound 10e: Take a 50 mL round-bottom flask, dissolve 1.05 mmol 9b in 8 mL dichloromethane, add 1.26 mmol cyclopropylamine, add 1.57 mmol N,N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel column for separation, and recrystallize from a dichloromethane-n-hexane mixed solvent. A white solid is obtained with a yield of 63% and a melting point of 241.9-242.9°C. 1 H NMR (400MHz, DMSO-d6) δ10.92(s,1H),9.26(s,1H),8.74(s,1H),8.23(d,J=59.0Hz,1H),7.77(d,J=9 .8Hz,1H),7.62(dd,J=10.2,6.4Hz,2H),2.81(d,J=134.6Hz,1H),0.77(d,J=6.9Hz,2H),0.59(s,2H). 13C NMR(100MHz,DMSO-d6)δ165.68,151.81,151.77,151.71,149.43,149.38,149.34,136.81,135.45,134.54,1 34.36,129.83,120.84,120.60,119.25,115.67,104.53,104.46,104.28,27.56,7.33.ESI-MS:461.990[M+H] + ,C 17 H 12 BrF4N3OS[460.98206].

[0122] Example 58: Preparation of compound 10f. The operation is the same as that of 53, except that isopropylamine is replaced by ethylamine. A white solid is obtained. Yield: 65%, melting point: 232.5-234.7°C. 1 H NMR (400MHz, DMSO-d6) δ10.48(s,1H),9.36(s,1H),8.12(s,1H),8.03(d,J=8.0Hz,1H),7.75(s,1H),7.66 –7.64(m,1H),7.51–7.48(m,1H),7.13(s,1H),3.48(t,J=6.8Hz,2H),2.24(d,J=1.9Hz,3H),1.13(s,3H). 13 C NMR(100MHz,DMSO-d6)δ181.12,165.12,158.62,156.23,135.38,135.34,124.90,124.73,123.05,1 23.01,120.74,120.50,119.37,119.29,115.61,115.39,14.88,14.85,14.46.ESI-MS:428.024[M+H] + ,C 17 H 16 BrF2N3OS[427.01655].

[0123] Example 59: Preparation of compound 10g. The operation is the same as 53, except that isopropylamine is replaced with 1,1,1-trifluoropropan-2-amine to obtain a white solid. Yield: 54%, melting point: 239.1-241.3°C. 1H NMR (400MHz, DMSO-d6) δ10.50(s,1H),9.57(s,1H),8.66(d,J=8.8Hz,1H),7.99(d,J=7.9Hz,1H),7.78(d,J=10.0Hz,1H),7.6 5(dd,J=7.1,2.6Hz,1H),7.50(dt,J=8.0,3.6Hz,1H),7.13(t,J=9.2Hz,1H),5.35(s,1H),2.24(s,3H),1.34(d,J=7.0Hz,3H). 13 C NMR (100MHz, DMSO-d6) δ182.72,165.01,158.64,156.25,135.50,135.47,135.30,124.91,124.73,123.08,123. 04,120.86,120.62,119.40,119.32,115.62,115.39,51.39,51.10,14.87,14.84,13.99.ESI-MS:496.005[M+H] + ,C 18 H 15 BrF5N3OS[495.00394].

[0124] Example 60: Preparation of compound 10h. The operation is the same as 53, except that isopropylamine is replaced with 4-trifluoromethylbenzylamine to obtain a white solid. Yield: 57%, melting point: 244.5-246.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.49(s,1H),9.66(s,1H),8.63(d,J=6.2Hz,1H),7.96(d,J=7.9Hz,1H),7.77(d,J=9.9Hz,1H),7.71(d,J=8. 1Hz,2H),7.66–7.64(m,1H),7.54(d,J=8.0Hz,2H),7.51(d,J=5.0Hz,1H),7.13(s,1H),4.85(d,J=5.5Hz,2H),2.24(d,J=1.9Hz,3H). 13C NMR(100MHz,DMSO-d6)δ182.30,165.03,156.25,144.24,135.52,135.31,135.29,128.40,128.16,125.67,125.63,125.60,1 24.91,124.73,123.07,123.02,120.97,120.73,119.38,119.30,115.61,115.38,47.42,14.87,14.84.ESI-MS:558.027[M+H] + ,C 23 H 17 BrF5N3OS[557.01959].

[0125] Example 61: Preparation of compound 10i. The operation is the same as 53, except that isopropylamine is replaced with 4-aminomethylphenylboronic acid to obtain a white solid. Yield: 57%, melting point: 250.2-251.9°C. 1 H NMR (400MHz, DMSO-d6) δ10.48(s,1H),9.54(s,1H),8.58(d,J=5.8Hz,1H),8.06(d,J=7.8Hz,1H),8.02(s,2H),7.77(d,J=6.8Hz,3H), 7.65(d,J=7.2Hz,1H),7.50(dd,J=8.1,3.5Hz,1H),7.30(d,J=7.5Hz,2H),7.13(t,J=8.7Hz,1H),4.75(d,J=5.5Hz,2H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ181.92,165.09,140.83,135.44,135.32,134.66,127.16,126.92,123.10,1 23.05,120.82,120.58,119.41,119.33,115.61,115.38,48.05,14.88,14.85.ESI-MS:532.0350[MH] - ,C 22 H 19 BBrF2N3O3S[533.03916].

[0126] Example 62: Preparation of compound 10j. The operation is the same as 53, except that isopropylamine is replaced by allylamine. A white solid is obtained with a yield of 59% and a melting point of 237.1-239.9°C. 1H NMR (400MHz, DMSO-d6) δ10.49(s,1H),9.48(s,1H),8.25(s,1H),8.04(d,J=8.0Hz,1H),7.75(d,J=10.0Hz,1H),7.67–7.64(m,1H),7.52–7.48 (m,1H),7.14(d,J=9.2Hz,1H),5.90(ddd,J=12.0,10.3,5.2Hz,1H),5.24–5.18(m,1H),5.15–5.11(m,1H),4.15(s,2H),2.24(d,J=1.9Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ181.66,165.09,158.62,156.24,135.33,135.30,134.85,124.91,124.73,123.06,12 3.01,120.77,120.53,119.37,119.29,116.45,115.61,115.38,46.83,14.88,14.85.ESI-MS:440.0246[M+H] + ,C 18 H 16 BrF2N3OS[439.01655].

[0127] Example 63: Preparation of compound 10k: Take a 50mL round-bottom flask, dissolve 1.05mmol 9c in 8mL dichloromethane, add 1.26mmol isopropylamine, add 1.57mmol N,N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel column for separation, and recrystallize from dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 59% and a melting point of 235.5-238.9℃. 1 H NMR (400MHz, DMSO-d6) δ10.26(s,1H),9.08(s,1H),7.87(s,2H),7.69–7.67(m,1H),7.52(dd,J=8.8,4.1Hz, 1H),7.21(d,J=11.5Hz,1H),7.11(s,1H),4.38(s,1H),2.37(s,3H),2.24(s,3H),1.18(s,3H),1.16(s,3H). 13C NMR(100MHz,DMSO-d6)δ180.49,166.88,158.48,156.10,135.63,135.60,133.13,124.73,124.55,123.16,1 23.12,119.43,119.35,118.09,117.88,115.48,115.25,22.40,19.44,14.89,14.86.ESI-MS:378.144[M+H] + ,C 19 H 21 F2N3OS[377.13734].

[0128] Example 64: Preparation of compound 101. The operation is the same as 63, except that isopropylamine is replaced by allylamine. A white solid is obtained. Yield: 51%. Melting point: 241.7-242.8°C. 1 H NMR (400MHz, DMSO-d6) δ10.28(s,1H),9.36(s,1H),8.05(s,1H),7.78(d,J=7.3Hz,1H),7.68(d,J=4.5Hz,1H),7.52(d,J=4.8Hz ,1H),7.25(s,1H),7.12(s,1H),5.91(dd,J=11.3,5.6Hz,1H),5.22(s,1H),5.13(s,1H),4.15(s,2H),2.38(s,3H),2.23(s,3H). 13 C NMR(100MHz,DMSO-d6)δ182.00,166.79,158.49,156.11,135.61,135.59,135.14,133.29,124.74,124.56,123.18,1 23.14,119.45,119.37,118.28,118.08,116.23,115.49,115.26,46.85,19.48,14.89,14.86.ESI-MS:376.126[M+H] + ,C 19 H 19 F2N3OS[375.12169].

[0129] Example 65: Preparation of compound 10m. The operation is the same as 63, except that isopropylamine is replaced with 4-aminomethylphenylboronic acid to obtain a white solid. Yield: 48%, melting point 253.5-255.9°C. 1H NMR (400MHz, DMSO-d6) δ10.26(s,1H),9.41(s,1H),8.36(s,1H),8.02(d,J=1.8Hz,2H),7.81(s,1H),7.76(d,J=7.6Hz,2H),7.66(d,J=7.1Hz, 1H),7.53–7.49(m,1H),7.29(d,J=7.5Hz,2H),7.24(d,J=11.3Hz,1H),7.11(t,J=9.2Hz,1H),4.75(d,J=5.2Hz,2H),2.38(s,3H),2.24(s,3H). 13 C NMR(100MHz,DMSO-d6)δ182.24,166.76,141.14,135.58,134.62,133.27,126.83,124.75,12 4.57,123.22,119.50,119.41,118.35,118.15,115.49,115.26,48.04,19.49,14.88,14.86.

[0130] Example 66: Preparation of compound 10n, the operation is the same as 63, except that isopropylamine is replaced by N-isopropylmethylamine, and a white solid is obtained, yield: 57%, melting point 233.6-235.0°C. ESI-MS: 392.161 [M+H] + ,C 20 H 23 F2N3OS[391.15299].

[0131] Synthesis Scheme 4

[0132]

[0133] Reagents and conditions: (i) ethyl oxalyl chloride, dichloromethane, 3 h, rt.; (ii) NaOH, methanol, water, 4 h, rt.; (iii) different types of amines, HATU, N,N-diisopropylethylamine, dichloromethane, 6 h, rt.

[0134] Example 67: Preparation of Intermediate 11: Take a 100 mL round-bottom flask, dissolve 5.86 mmol 5a in 15 mL dichloromethane, add 5.86 mmol ethyl oxalyl chloride, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, concentrate, dry sample, separate by rapid preparative chromatography on silica gel column, and recrystallize in dichloromethane solvent. The product is a white solid with a yield of 64% and a melting point of 217.6-218.5°C.

[0135] Example 68: Preparation of intermediate 12: Take a 50 mL round-bottom flask, dissolve 2.27 mmol 11 in 4 mL methanol, add 1 mL 4N NaOH solution, and stir under ice bath. TLC monitors the reaction. After the reaction is complete, adjust the pH to 3-4 with 2N HCl, extract with ethyl acetate (20 mL × 3), combine the organic phases, wash with saturated brine (20 mL × 3), dry with anhydrous sodium sulfate, concentrate, dry sample, separate with rapid preparative silica gel chromatography, and recrystallize with dichloromethane solvent. The product is a light yellow solid, yield: 56%, melting point 225.7-227.9 ° C.

[0136] Example 69: Preparation of compound 13a. Take a 50 mL round-bottom flask, dissolve 1.02 mmol of 12 in 6 mL of dichloromethane, add 1.22 mmol of isopropylamine, 3.05 mmol of HATU, and 3.05 mmol of N,N-diisopropylethylamine, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, add water (20 mL × 3), combine the organic phases, wash with saturated brine (20 mL × 3), dry with anhydrous sodium sulfate, concentrate, dry-load, separate with a rapid preparative chromatography silica gel column, and recrystallize with a dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 53% and a melting point of 232.2-234.6°C. 1 H NMR (400MHz, DMSO-d6) δ10.54(s,1H),10.48(s,1H),8.89(d,J=8.4Hz,1H),7.85–7.81(m,2H),7.65(d,J=6.4Hz,1 H),7.51–7.48(m,1H),7.13(s,1H),4.02–3.97(m,1H),2.24(s,3H),1.17(d,J=1.7Hz,3H),1.15(d,J=1.6Hz,3H). 13 C NMR(100MHz,DMSO-d6)δ164.96,159.42,158.65,154.07,135.97,135.27,125.55,124.96,124.78,123.04,1 22.99,121.03,120.80,119.35,119.27,115.65,115.42,41.89,22.21,14.87,14.83.ESI-MS:454.057[M+H] + ,C 19 H 18 BrF2N3O3[453.04996].

[0137] Example 70: Preparation of compound 13b. The operation is the same as that of 69, except that isopropylamine is replaced by cyclopentylamine. A white solid is obtained. Yield: 42%. Melting point: 235.5-237.2°C. 1 H NMR (400MHz, DMSO-d6) δ10.55(s,1H),10.49(s,1H),8.98(d,J=8.0Hz,1H),7.85–7.80(m,2H),7.64(d,J=7.0Hz,1H),7.51–7.47( m,1H),7.15(d,J=9.2Hz,1H),4.14–4.08(m,1H),2.24(s,3H),1.88–1.83(m,2H),1.71–1.66(m,2H),1.55(dt,J=10.8,5.9Hz,4H). 13 C NMR (100MHz, DMSO-d6) δ164.96,159.37,159.25,156.27,154.08,135.96,135.27,125.58,124.96,124.89,124.78,123. 02,122.97,121.04,120.81,119.34,119.26,115.65,115.42,51.44,32.06,24.04,14.87,14.84.ESI-MS:480.073[M+H] + ,C 21 H 20 BrF2N3O3[479.06561].

[0138] Example 71: Preparation of compound 13c, the operation is the same as 69, except that isopropylamine is replaced with 1-amino-2-methyl-2-propanol, to obtain a white solid, yield: 39%, melting point 238.0-239.7°C. ESI-MS: calculated for C 20 H 20 BrF2N3O4[MH] - 483.06053, found 484.068.

[0139] Example 72: Preparation of compound 13d. The operation is the same as that of 69, except that isopropylamine is replaced by cyclopropylamine to obtain a white solid. Yield: 35%, melting point: 232.7-234.3°C. 1H NMR (400MHz, DMSO-d6) δ10.56(s,1H),10.51(s,1H),9.13(d,J=5.3Hz,1H),7.82(d,J=9.3Hz,1H),7.64(dd,J=7.1,2.6Hz,1H),7.52(d, J=4.0Hz,1H),7.49–7.46(m,1H),7.14(d,J=9.2Hz,1H),2.85(dd,J=8.1,3.8Hz,1H),2.24(d,J=1.9Hz,3H),0.69(dd,J=6.7,4.5Hz,4H). 13 C NMR(100MHz,DMSO-d6)δ164.96,160.88,159.13,158.65,151.60,135.96,135.92,135.27,135.24,135.10,129.34, 125.62,124.78,121.20,121.04,119.32,119.24,115.65,115.42,23.53,14.88,14.84,5.92.ESI-MS:452.041[M+H] + ,C 19 H 16 BrF2N3O3[451.03431].

[0140] Synthesis Scheme 5

[0141]

[0142] Reagents and conditions: (i) concentrated HNO3, concentrated H2SO4, 0℃, 12h, rt.; (ii) thionyl chloride, N,N-dimethylformamide, 6h, 80℃; (iii) acetonitrile, 3,4,5-trifluoroaniline, 6h, 60℃; (iv) Fe powder, NH4Cl, methanol, water, 12h, 90℃; (v) phenyl chloroformate, pyridine, dichloromethane, 6h, rt.; (vi) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4h, rt.

[0143] Example 73: Preparation of Compound 15: Take a 100 mL round-bottom flask, add 22.5 mL of concentrated H2SO4, add 22.83 mmol of 2-bromo-6-fluorobenzoic acid under ice bath, slowly add 2 mL of concentrated HNO3, react at room temperature for 12 h. After the reaction, add dropwise 200 mL of ice water, filter, wash with water, and dry to obtain 4.1004 g of yellow-white solid, with a yield of 68%.

[0144] Example 74: Preparation of compound 16: Take a 50 ml round-bottom flask, dissolve 3.21 mmol of intermediate 15 in 10 mL of thionyl chloride, add 2 drops of N,N-dimethylformamide, reflux at 80°C, cool to room temperature after the reaction, and obtain an oily product after rotary evaporation.

[0145] Example 75: Preparation of intermediate 17. Take a 50 mL round-bottom flask, dissolve intermediate 16 in 15 mL acetonitrile, add 3,4,5-trifluoroaniline, reflux at 60°C, cool to room temperature after the reaction, concentrate, dry load, quickly prepare silica gel chromatography column for separation, and recrystallize using a dichloromethane-n-hexane mixed solvent.

[0146] Example 76: Preparation of intermediate 18. Take a 100mL round-bottom flask, dissolve 5.39mmol of intermediate 17 in a mixed solvent of methanol (10mL) and water (10mL), add 18.86mmol Fe powder and 10.78mmol NH4Cl, and reflux at 90℃. After the reaction is completed, use diatomaceous earth to filter while hot. The filtrate is concentrated and dried to obtain a white solid. The yield is 78%.

[0147] Example 77: Preparation of intermediate 19: Take a 50 mL round-bottom flask, dissolve 2.93 mmol of 18 in 10 mL of dichloromethane, add 3.52 mmol of phenyl chloroformate, add 8.79 mmol of pyridine, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, remove dichloromethane by rotary evaporation, add 2N HCl solution for extraction, combine the organic phases, wash with saturated brine (20 mL × 3), dry with anhydrous sodium sulfate, concentrate, dry-load, separate by rapid preparative silica gel chromatography, and recrystallize to obtain the target compound. The product is a white solid with a yield of 60% and a melting point of 207.1-208.7°C.

[0148] Example 78: Preparation of compound 20a: Take a 50 mL round-bottom flask, dissolve 1.08 mmol of 19 in 8 mL of dichloromethane, add 1.30 mmol of 4-hydroxybenzylamine, add 1.63 mmol of N,N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel column for separation, and recrystallize from a dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 58% and a melting point of 234.1-236.4°C. 1 H-NMR (400MHz, Chloroform-d) δ8.59 (s, 1H), 7.71–7.64 (m, 1H), 7.52 (d, J = 8.6Hz, 1H), 7. 43–7.33(m,2H),4.90(d,J=7.5Hz,1H),3.50(h,J=6.7Hz,1H),1.11(dd,J=6.6,1.7Hz,6H). 13C-NMR(100MHz,Chloroform-d)δ160.20,156.55,153.98,150.01,131.29,129.14,129.10,128.71,128.56,128.39,128.17, 126.46,126.42,104.89,104.82,104.71,104.64,60.55,46.97,29.72,26.93,23.60,21.06,14.16.ESI-MS:523.096[MH]-,C 24 H 20 F4N2O5S[524.10291].

[0149] Example 79: Preparation of compound 20b. The operation is the same as Example 78, except that the isopropyl group is replaced by cyclohexylamine. The product is a white solid with a yield of 60% and a melting point of 238.6-241.2°C. 1 H-NMR (400MHz, DMSO-d6) δ11.17(s,1H),8.13(dd,J=9.3,5.6Hz,1H),7.91(s,1H),7.66–7.54(m,2H),7.36(t,J=8.8Hz,1H),7.03(d,J =7.6Hz,1H),3.48(d,J=9.3Hz,1H),1.88–1.77(m,2H),1.72–1.62(m,2H),1.55(d,J=12.6Hz,1H),1.23(dq,J=45.3,11.3,10.8Hz,5H). 13 C-NMR(100MHz,DMSO-d6)δ176.50,175.40,169.73,162.32,154.46,152.22,152.03,132.43,130.96,12 3.69,117.56,104.38,104.14,34.48,33.28,26.56,25.69,24.72,22.38,18.72.ESI-MS:488.0424[M+H] + ,C 20 H 18 BrF4N3O2[487.05185].

[0150] Example 80: Preparation of compound 20c. The operation is the same as Example 78, except that the isopropyl group is replaced by 3,4,5-trifluoroaniline. The product is a white solid with a yield of 47% and a melting point of 221.7-223.6°C. 1H-NMR (400MHz, DMSO-d6) δ11.06 (s, 1H), 7.59 (dd, J = 10.0, 6.4Hz, 2H), 7.13 (t, J=8.8Hz,1H),6.91(dd,J=9.2,5.3Hz,1H),5.44(s,2H),4.38(d,J=1.5Hz,1H). 13 C-NMR(100MHz,DMSO-d6)δ162.92,151.27,149.53,148.92,143.78,131.82,129.00,127.47,127.25,116.4 1,116.33,116.19,115.97,104.28,104.22,104.03,65.54,56.51,29.52,19.01.ESI-MS:533.9669[MH]-,C 22 H 16 BrF4N3O3[534.97664].

[0151] Example 81: Preparation of compound 20d. The operation is the same as Example 78, except that the isopropyl group is replaced by 4-trifluoromethylaniline. The product is a white solid with a yield of 45% and a melting point of 229.8-232.4°C. 1 H-NMR (400MHz, DMSO-d6) δ11.05(s,2H),7.59(dd,J=10.2,6.4Hz,4H),7.12(td,J=8.8,1.6Hz,2H),6.95–6.86(m,2H),4.27–3.94(m,1H). 13 C-NMR (100MHz, DMSO-d6) δ162.91,152.00,151.26,149.57,148.91,143.80,127.48,127.26,116.40,116. 32,116.19,115.97,104.27,104.22,104.03,34.77,31.62,30.83,30.40,30.30.ESI-MS:547.9852[MH]-,C 21 H 11 BrF7N3O2[548.99229].

[0152] Example 82: Preparation of compound 20e. The operation is the same as Example 78, except that the isopropyl group is replaced by 3,4,5-trifluorobenzylamine. The product is a white solid with a yield of 54% and a melting point of 252.4-255.8°C. 1H-NMR(400MHz,DMSO-d6)δ11.17(s,1H),8.17(s,1H),8.12–8.06(m,1H),7.72(d ,J=7.9Hz,2H),7.62–7.51(m,5H),7.37(t,J=8.8Hz,1H),4.42(d,J=5.8Hz,2H). 13 C-NMR(100MHz,DMSO-d6)δ162.25,155.54,155.02,152.59,152.07,145.42,143.29,135.41,128.26,127.87,126.1 9,125.77,125.73,124.66,123.49,115.82,115.60,104.41,104.16,56.50,42.95,19.02.ESI-MS:547.9963[MH]-,C 21 H 11 BrF7N3O2[548.99229].

[0153] Example 83: Preparation of compound 20f. The operation is the same as Example 78, except that the isopropyl group is replaced by 4-trifluoromethylaniline. The product is a white solid with a yield of 57% and a melting point of 249.3-252.0°C. 1 H-NMR(400MHz,DMSO-d6)δ11.17(s,1H),8.17(s,1H),8.12–8.06(m,1H),7.72(d ,J=7.9Hz,2H),7.62–7.51(m,5H),7.37(t,J=8.8Hz,1H),4.42(d,J=5.8Hz,2H). 13 C-NMR(100MHz,DMSO-d6)δ162.25,155.54,155.02,152.59,152.07,145.42,143.29,135.41,128.26,127.87,126.1 9,125.77,125.73,124.66,123.49,115.82,115.60,104.41,104.16,56.50,42.95,19.02.ESI-MS:562.0042[MH]-,C 22 H 13 BrF7N3O2[563.00794].

[0154] Example 84: Preparation of compound 20g. The operation is the same as Example 78, except that the isopropyl group is replaced by 4-fluorobenzylamine. The product is a white solid with a yield of 61% and a melting point of 245.1-248.7°C. 1H-NMR(400MHz,DMSO-d6)δ11.17(s,1H),8.15–8.06(m,2H),7.59(dd,J=10.1,6.4Hz,2H),7 .47(d,J=5.9Hz,1H),7.40–7.33(m,3H),7.18(td,J=8.9,1.7Hz,2H),4.31(d,J=5.6Hz,2H). 13 C-NMR (100MHz, DMSO-d6) δ162.92,162.26,155.40,152.49,136.52,136.48,135.49,135.46,129.76,129.68 ,127.62,124.43,124.35,115.80,115.70,115.58,115.49,111.46,104.40,104.16.ESI-MS:514.0276[M+H] + ,C 22 H 13 BrF5N3O2[513.01113].

[0155] Example 85: Preparation of compound 20h. The operation is the same as Example 78, except that the isopropyl group is replaced by 4-methoxybenzylamine. The product is a white solid with a yield of 59% and a melting point of 253.5-256.2°C. 1 H-NMR (400MHz, DMSO-d6) δ11.17(s,1H),8.13(dd,J=9.5,5.6Hz,1H),8.05(s,1H),7.59(dd,J=10.0,6.3Hz,2H),7 .38(q,J=8.9,7.9Hz,2H),7.24(d,J=8.0Hz,2H),6.95–6.87(m,2H),4.24(d,J=5.5Hz,2H),3.74(d,J=1.5Hz,3H). 13 C-NMR(100MHz,DMSO-d6)δ162.27,158.81,155.30,154.81,152.39,135.57,132.08,129.16,127.6 0,124.16,115.79,115.57,114.29,111.25,104.39,104.15,55.56,42.88.ESI-MS:526.0609[M+H] + ,C 22 H 16 BrF4N3O3[525.03112].

[0156] Synthesis Scheme 6

[0157]

[0158] Reagents and conditions: (i) phenyl chlorothioate, pyridine, dichloromethane, 6 h, rt.; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt.

[0159] Example 86: Preparation of intermediate 21: Take a 50 mL round-bottom flask, dissolve 2.93 mmol of 18 in 10 mL of dichloromethane, add 3.52 mmol of phenyl chlorothioformate, add 8.79 mmol of pyridine, and stir at room temperature. Monitor the reaction by TLC. After the reaction is complete, remove dichloromethane by rotary evaporation, add 2N HCl solution for extraction, combine the organic phases, wash with saturated brine (20 mL × 3), dry with anhydrous sodium sulfate, concentrate, dry-load, separate by rapid preparative silica gel chromatography, and recrystallize with dichloromethane solvent. The product is a light yellow solid with a yield of 59% and a melting point of 213.8-214.6°C.

[0160] Example 87: Preparation of compound 22a: Take a 50 mL round-bottom flask, dissolve 1.05 mmol of 21 in 8 mL of dichloromethane, add 1.26 mmol of 3-pentylamine, add 1.57 mmol of N,N-diisopropylethylamine, and stir at room temperature. After the reaction is completed, concentrate, dry sample, quickly prepare silica gel chromatography column for separation, and recrystallize from a dichloromethane-n-hexane mixed solvent. The product is a white solid with a yield of 61% and a melting point of 240.0-242.7°C. 1 H-NMR (600MHz, DMSO-d6) δ11.23(s,1H),8.97(s,1H),7.93(d,J=8.5Hz,1H),7.82–7.77(m,1H),7.60(dd,J=9.9,6. 3Hz,2H),7.41(t,J=8.7Hz,1H),4.20(d,J=7.1Hz,1H),1.61–1.52(m,2H),1.51–1.44(m,2H),0.89(t,J=7.4Hz,6H). 13 C-NMR(150MHz,DMSO-d6)δ182.24,162.06,155.24,151.56,149.93,135.61,135.28,135.20,132.41,1 27.79,118.76,115.32,115.17,104.39,104.25,104.22,56.74,26.71,10.62.ESI-MS:492.038[MH]-,C 19 H 18 BrF4N3OS[491.02901].

[0161] Example 88: Preparation of compound 22b. The operation is the same as Example 87, except that 3-pentylamine is replaced by cyclopentylamine. The product is a white solid with a yield of 65% and a melting point of 242.7-245.2°C. 1 H-NMR (600MHz, DMSO-d6) δ11.24(s,1H),8.94(s,1H),8.18(d,J=6.9Hz,1H),7.85(d,J=19.0Hz,1H),7.60(dd,J=9.9, 6.4Hz,2H),7.40(t,J=8.7Hz,1H),4.50(s,1H),2.00–1.92(m,2H),1.72–1.62(m,2H),1.60–1.52(m,2H),1.48(s,2H). 13 C-NMR(150MHz,DMSO-d6)δ162.07,151.57,149.94,135.30,132.09,127.77,127.62 ,115.29,115.14,104.39,56.01,33.23,32.59,23.87,23.63.ESI-MS:490.023[M+H] + ,C 19 H 16 BrF4N3OS[489.01336].

[0162] Example 89: Preparation of compound 22c. The operation is the same as that of Example 87, except that 3-pentylamine is replaced with (S)-3-aminotetrahydrofuran. The product is a white solid with a yield of 45% and a melting point of 248.1-253.9°C. 1 H-NMR (600MHz, DMSO-d6) δ11.24(s,1H),9.06(s,1H),8.41(d,J=6.7Hz,1H),7.60(dd,J=9.8,6.3Hz,2H),7.42(t,J=8.7Hz ,1H),4.74(s,1H),3.89–3.77(m,2H),3.72(d,J=5.6Hz,1H),3.65(dd,J=9.6,3.0Hz,1H),2.26–2.18(m,1H),1.86(s,1H). 13 C-NMR(150MHz,DMSO-d6)δ162.02,151.56,149.94,135.25,135.17,127.85,127.69,115.41,11 5.26,104.39,104.22,73.03,66.84,60.25,55.39,55.28,32.58,14.55.ESI-MS:492.000[M+H]+ ,C 18 H 14 BrF4N3O2S[490.99202].

[0163] Example 90: Preparation of compound 22d. The operation is the same as Example 87, except that 3-pentylamine is replaced by cyclohexylamine. The product is a white solid with a yield of 60% and a melting point of 239.7-244.6°C. 1 H-NMR (600MHz, DMSO-d6) δ11.24(s,1H),8.99(s,1H),8.09–7.99(m,1H),7.81(s,1H),7.60(dd,J=9.8,6.3Hz,2H),7.40(t,J=8.7 Hz,1H),4.08(s,1H),1.94(dt,J=12.4,3.9Hz,2H),1.70(dq,J=7.6,3.6Hz,2H),1.57(dd,J=10.9,6.9Hz,1H),1.36–1.14(m,5H). 13 C-NMR (150MHz, DMSO-d6) δ162.06,151.56,149.93,135.58,135.28,132.22,127.78,127.63,118. 47,115.30,115.15,104.38,104.25,104.21,52.95,32.36,25.60,24.90.ESI-MS:502.028[MH]-,C 20 H 18 BrF4N3OS[503.02901].

[0164] Example 91: In vitro anti-HBV cell activity test of target compound

[0165] HBV cell lines and culture conditions

[0166] HepAD38 cells were revived and digested after being fully grown and counted. Tetracycline (final concentration of 300 ng / mL) and G418 (final concentration of 400 μg / mL) were added to the culture medium. The virus was not expressed in the presence of Tetracycline. The cells were diluted to a concentration of 2×10 with DMEM / F-12K culture medium containing 10% FBS (containing Tetracycline at a final concentration of 300 μg / mL and G418 at a final concentration of 400 μg / ml, 1% double antibody). 5 / mL cell suspension, inoculate 100 μL per well in a 96-well plate (cover the entire plate), and incubate in a 37°C, 5% CO2 constant temperature incubator for 24 hours. After 24 hours, discard the old culture medium and add 200 μL of fresh DMEM / F-12K culture medium containing 2% FBS and 1% double antibody.

[0167] (1) Cytotoxicity assay

[0168] Compound preparation and cell treatment in in vitro cytotoxicity assay: Dissolve the compound in DMSO to 20 mM. Add 1 μL of serially diluted compound to each well of the above cell plate, with the highest final concentration of 100 μM (200-fold dilution). Staurosporine (Selleck, CAS No. 62996-74-1) was used as a positive control compound with a maximum concentration of 1 μM. Add 1 μL of DMSO to the negative control wells, with a final concentration of 0.5%.

[0169] After 72 hours, the old culture medium was discarded and culture medium containing 10% CCK8 solution was added. The cells were incubated for 20-40 minutes and detected in a microplate reader to obtain the OD value. The data were exported to calculate the inhibition rate. The experimental data were analyzed and processed using Graphpad Prism 8 software. Quantitative data with normal distribution were statistically described using mean ± standard error (Means ± SEM).

[0170] (2) HBV DNA activity inhibition experiment (quantitative PCR method)

[0171] Compound preparation and cell treatment in antiviral experiments: Dissolve the compound to 20mM with DMSO, then dilute it 4 times with 8 dilutions, the highest concentration is 20μM, 2 replicates. QPCR was performed using the one-step hepatitis B virus nucleic acid quantitative detection kit for 48 people (PCR-fluorescent probe method) of Shengxiang Biotechnology. 2.5μL of supernatant was aspirated for Q-PCR. After the reagents of the kit were melted before use, vortexed and mixed. After centrifugation, the enzyme mixture was placed on ice for use, and the subsequent steps were completed on ice. 2.5μL of sample release agent and 2.5μL of test sample supernatant were added to each well of the Q-PCR plate (experimental group, control group, standard curve group). The number of viral DNA copies in each well was obtained after Q-PCR reaction. Graphpad Prism 8 software was used to analyze and process the experimental data, and the quantitative data that obeyed the normal distribution were statistically described using mean ± standard error (Means ± SEM).

[0172] Table 1 Anti-HBV activity of directed synthetic compounds and lead compound NVR 3-778

[0173]

[0174]

[0175] The activity results showed that the newly synthesized benzamide HBV capsid protein inhibitors showed significant anti-HBV activity. Among them, compound 101 had the best activity (EC 50 =0.012±0.002μM), which is significantly better than the lead compound NVR 3-778 and is worthy of further study.

[0176] Example 92: In vitro anti-HBV target activity experiment of target compound

[0177] The HBV core protein was incubated with fluorescent dye at 4°C overnight to label the C150 protein, and the excess fluorescent dye was removed by dextran gel filtration. Then, the fluorescently labeled HBV core protein was incubated with different concentrations of compounds at room temperature for 15 minutes, and NaCl was added. After incubation at room temperature for 1 hour, the fluorescence signal value (Ex485 / Em535) was measured using a microplate reader SpectraMax M2.

[0178] The starting concentration of the compound test was 30 μM, 3-fold serial dilution, 8 concentrations in total, 2 replicates. The final concentration of fluorescently labeled HBV core protein in the compound test system was 1.5 μM, the final concentration of NaCl was 150 mM, the concentration of DMSO was 0.5%, and 0% assembly control wells (0 M NaCl) and 100% assembly control wells (1 M NaCl) were set at the same time.

[0179] Assembly activity % = [1-(sample fluorescence - 1M NaCl average control fluorescence value) / (0M NaCl average control fluorescence value - 1M NaCl average control fluorescence value)] × 100. Graphpad Prism 5 software was used to analyze and process the experimental data and images, and statistical descriptions were performed.

[0180] Table 2 Target activity assay results of lead compounds and compounds 10a, 10i and 10l

[0181]

[0182] According to the target activity results, 10i (EC 50 =22.3650±2.52μM) was weaker than the lead compound NVR 3-778 (EC 50 =1.5260±0.19μM), while 10a (EC 50 =0.7412 μM) and 10 l (EC 50 =0.8780±0.04μM) target activity was better than that of the lead compound.

Claims

1. A benzamide HBV capsid protein inhibitor, It is characterized in that It has the structure shown in the following general formula I: Among them, Z is L is R 1 -CH 3 or Br, R 2 -CH 3 or F, R 3 It is H or F.

2. A benzamide HBV capsid protein inhibitor according to claim 1, It is characterized in that It is one of the compounds having the following structures:

3. The method for preparing the benzamide HBV capsid protein inhibitor according to claim 2, Features Using 2-bromo-4-fluorobenzoic acid and 2-methyl-4-fluorobenzoic acid as raw materials, it is prepared by one of the following synthetic routes: Synthesis route 1 is as follows: Reagents and conditions: (i) Concentrated HNO 3 , concentrated H 2 SO 4 , 0℃, 12h, rt; (ii) thionyl chloride, N,N-dimethylformamide, 6h, 80℃; (iii) acetonitrile, 3-fluoro-4-methylaniline or 3,4,5-trifluoroaniline, 6h, 60℃; (iv) Fe powder, NH 4 Cl, methanol, water, 12 h, 90 °C; (v) different types of acyl chlorides, pyridine, dichloromethane, 4 h, rt; The different types of acyl chlorides are selected from: 4-cyanobenzoyl chloride, 4-bromobenzoyl chloride, 4-methylbenzoyl chloride, 4-n-propylbenzoyl chloride, 2-thiophenecarbonyl chloride, (E)-phenylacryloyl chloride, 3,4,5-trifluorobenzoyl chloride, 4-trifluoromethylbenzoyl chloride, 4-fluorobenzoyl chloride, 4-fluorophenylacetyl chloride, acryloyl chloride, 2-butenoyl chloride, cyclopropylcarbonyl chloride, cyclobutylcarbonyl chloride, cyclopentylcarbonyl chloride, cyclohexylcarbonyl chloride, 4-methoxybenzoyl chloride; Synthesis route 2 is as follows: Reagents and conditions: (i) phenyl chloroformate, pyridine, dichloromethane, 6 h, rt; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt; The different types of amines are selected from: 4-hydroxybenzylamine, 3,5-difluorobenzylamine, 3-methyl-4-fluorobenzylamine, 4-trifluoromethylbenzylamine, 4-fluorobenzylamine, 3-aminomethylpyridine, 3,4,5-trifluorobenzylamine, 3-pentylamine, isopropylamine, 3,4,5-trifluoroaniline, 4-tert-butylbenzylamine, 4-hydroxypiperidine, 4-trifluoromethylaniline, cyclopentylamine, 4-hydroxycyclohexylamine, 4-methoxybenzylamine; Synthesis route 3 is as follows: Reagents and conditions: (i) phenyl chlorothioate, pyridine, dichloromethane, 6 h, rt; (ii) different types of amines, N,N-diisopropylethylamine, dichloromethane, 4 h, rt; The different types of amines are selected from the group consisting of isopropylamine, 4-fluorobenzylamine, 3,5-difluorobenzylamine, 3-methyl-4-fluorobenzylamine, cyclopropylamine, ethylamine, allylamine, 4-trifluoromethylbenzylamine, 4-aminomethylphenylboronic acid, and N-isopropylmethylamine; Synthesis route 4 is as follows: Reagents and conditions: (i) ethyl oxalyl chloride, dichloromethane, 3 h, rt; (ii) NaOH, methanol, water, 4 h, rt; (iii) different types of amines, HATU, N,N-diisopropylethylamine, dichloromethane, 6 h, rt; The different types of amines are selected from: isopropylamine, cyclopentylamine, 1-amino-2-methyl-2-propanol, cyclopropylamine; The R in the above route 1 , R 2 , R 3 , L are as described in the corresponding positions of the above-mentioned compounds of general formula I.

4. Use of the benzamide HBV capsid protein inhibitor according to any one of claims 1 to 2 in the preparation of anti-hepatitis B drugs.

5. An anti-HBV pharmaceutical composition comprising the benzamide HBV capsid protein inhibitor according to any one of claims 1-2 and one or more pharmaceutically acceptable carriers.